# DataMeds AI, Inc.: overview MEDS · Nasdaq · CIK 2030763 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/meds.md) · [Financials](/companies/meds/financials.md) · [Filings](/companies/meds/filings.md) · [Insiders](/companies/meds/insiders.md) Latest reported revenue: [$1.8m](/filings/0001493152-26-038581.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 17, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-038581). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [5.7](/filings/0001493152-25-024328.md) | [12.4 d](/filings/0001493152-26-012004.md) | [10.9](/filings/0001493152-26-024413.md) | [7.8](/filings/0001493152-26-038581.md) | [3.0](/filings/0001493152-25-024328.md) | [1.7 d](/filings/0001493152-26-012004.md) | [1.6](/filings/0001493152-26-024413.md) | [1.8](/filings/0001493152-26-038581.md) | | Gross margin | % | [9.2%](/filings/0001493152-25-024328.md) | [10.1% d](/filings/0001493152-26-012004.md) | [6.4%](/filings/0001493152-26-024413.md) | [6.5%](/filings/0001493152-26-038581.md) | [7.7%](/filings/0001493152-25-024328.md) | [(470.2%) d](/filings/0001493152-26-012004.md) | [10.9%](/filings/0001493152-26-024413.md) | [10.2%](/filings/0001493152-26-038581.md) | | Operating margin | % | [(30.8%)](/filings/0001493152-25-024328.md) | [(30.2%) d](/filings/0001493152-26-012004.md) | [(288.6%)](/filings/0001493152-26-024413.md) | [(70.6%)](/filings/0001493152-26-038581.md) | [(1047.1%)](/filings/0001493152-25-024328.md) | [(1517.5%) d](/filings/0001493152-26-012004.md) | [(385.7%)](/filings/0001493152-26-024413.md) | [(412.7%)](/filings/0001493152-26-038581.md) | | Net margin | % | [(32.9%)](/filings/0001493152-25-024328.md) | [(34.9%) d](/filings/0001493152-26-012004.md) | [(298.5%)](/filings/0001493152-26-038581.md) | [(85.6%)](/filings/0001493152-26-038581.md) | [(1139.0%)](/filings/0001493152-25-024328.md) | [(1667.2%) d](/filings/0001493152-26-012004.md) | [(496.5%)](/filings/0001493152-26-038581.md) | [(1031.7%)](/filings/0001493152-26-038581.md) | | Diluted EPS | $ per share | [(0.04)](/filings/0001493152-25-024328.md) | not reported | [(0.62)](/filings/0001493152-26-024413.md) | [(5.40)](/filings/0001493152-26-038581.md) | [(0.46)](/filings/0001493152-25-024328.md) | not reported | [(0.07)](/filings/0001493152-26-024413.md) | [(7.13)](/filings/0001493152-26-038581.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | [18.1](/filings/0001493152-26-012004.md) | [23.3](/filings/0001493152-26-012004.md) | | Gross margin | % | not reported | [9.7%](/filings/0001493152-26-012004.md) | [(27.5%)](/filings/0001493152-26-012004.md) | | Operating margin | % | not reported | [(33.9%)](/filings/0001493152-26-012004.md) | [(401.7%)](/filings/0001493152-26-012004.md) | | Net margin | % | not reported | [(37.8%)](/filings/0001493152-26-012004.md) | [(433.9%)](/filings/0001493152-26-012004.md) | | Diluted EPS | $ per share | [(0.06)](/filings/0001641172-25-000612.md) | [(0.15)](/filings/0001493152-26-012004.md) | [(1.43)](/filings/0001493152-26-012004.md) | | Free cash flow | $m | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/meds/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $63.6k | 20,532 | | New +20,532 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $38.6k | 12,467 | | New +12,467 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $34.4k | 11,085 | | New +11,085 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $19.2k | 6,191 | | New +6,191 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $2.2k | 723 | | New +723 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.1k | 678 | | New +678 | | [Fortitude Family Office, LLC](/funds/1950506.md) | 2026-06-30 | $366 | 118 | | New +118 | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $78 | 25 | | New +25 | | [Global Retirement Partners, LLC](/funds/1749744.md) | 2026-06-30 | $6 | 2 | | Not compared | | [DANSKE BANK A/S](/funds/800177.md) | 2026-06-30 | $3 | 1 | | New +1 | ## Recent filings [All 175 filings](/companies/meds/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 17:00 ET | [8-K](/filings/0001493152-26-048573.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-048573 | | 2026-10-20 | 09:24 ET | [8-K](/filings/0001493152-26-047711.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-047711 | | 2026-10-16 | 17:15 ET | [8-K](/filings/0001493152-26-047451.md) | 1.01 Entry into a material agreement; 3.01 Delisting notice; 3.02 Unregistered sale of equity | 0001493152-26-047451 | | 2026-10-13 | 17:27 ET | [8-K](/filings/0001493152-26-046887.md) | 8.01 Other events | 0001493152-26-046887 | | 2026-10-09 | 17:20 ET | [S-1/A](/filings/0001493152-26-046608.md) | Registration statement, amended | 0001493152-26-046608 | | 2026-09-17 | 17:23 ET | [8-K](/filings/0001493152-26-043169.md) | 8.01 Other events | 0001493152-26-043169 | | 2026-09-16 | 17:11 ET | [8-K](/filings/0001493152-26-042951.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042951 | | 2026-08-18 | 07:43 ET | [8-K](/filings/0001493152-26-038891.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-038891 | | 2026-08-17 | 06:05 ET | [10-Q](/filings/0001493152-26-038581.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038581 | | 2026-08-14 | 16:46 ET | [8-K](/filings/0001493152-26-038475.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-038475 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012004.md), filed Mar 20, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f7eb337b-3a29-4ebe-86da-1d40fe7d1360) ## About the filer - CIK: 2030763 - Tickers: MEDS - Exchange: Nasdaq - SIC code: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:01 ET. No prices; not investment advice.